Ever Supreme Bio Technology Co

Ever Supreme Bio Technology Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ever Supreme Bio Technology Co (6712.TWO) as of Oct 16, 2026 is 438.94 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 465.64 M TWD — a change of -5.73% (lower).

EBITDA

438.94 MTWD

YoY

-5.73%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ever Supreme Bio Technology Co is 2025 438.94 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ever Supreme Bio Technology Co was 2024 465.64 M TWD. It decreases by -5.73% lower compared to the previous year.

The Ever Supreme Bio Technology Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-87.55 M TWD
Jan 1, 2019
-135.49 M TWD
Jan 1, 2020
-136.62 M TWD
Jan 1, 2021
397.44 M TWD
Jan 1, 2022
264.61 M TWD
Jan 1, 2023
623.22 M TWD
Jan 1, 2024
465.64 M TWD
Jan 1, 2025
438.94 M TWD
The Ever Supreme Bio Technology Co EBITDA history
YEAREBITDAYoY
438.94 MTWD-5.73%
465.64 MTWD-25.28%
623.22 MTWD+135.52%
264.61 MTWD-33.42%
397.44 MTWD-390.91%
-136.62 MTWD+0.84%
-135.49 MTWD+54.75%
-87.55 MTWD+119.16%
-39.95 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ever Supreme Bio Technology Co Stock analysis

What does Ever Supreme Bio Technology Co do? Ever Supreme Bio Technology Co Ltd is a biotechnology company based in Taichung, Taiwan, operating within the healthcare sector. The company has 8 employees and went public on October 26, 2018. It focuses on the research, development, and sale of stem cell products. The company's website is https://www.ever-supreme.com.tw/. Ever Supreme Bio Technology Co Ltd is engaged in the development of stem cell-based therapies, with specific products including ADCV01, a dendritic cell tumor vaccine currently in Phase II clinical trials in Taiwan. The company also develops UMSC01, a human allogeneic umbilical cord stem cell product intended for the treatment of myocardial infarction. UMSC01 is approved for Phase I clinical trials by the U.S. Food and Drug Administration (FDA) and is undergoing regulatory processes in Taiwan. Additionally, the company is involved in the development of stem cell treatments for acute ischemic stroke, with clinical Phase I trials pending in the United States. The company has plans to expand its product portfolio to include mesenchymal stem cells for multiple sclerosis treatment. Ever Supreme Bio Technology Co Ltd is listed on the Taiwan Stock Exchange under ticker 6712.TWO with ISIN TW0006712003. The company's operations are centered around innovative biotechnology solutions aimed at addressing critical healthcare needs. Ever Supreme Bio Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ever Supreme Bio Technology Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ever Supreme Bio Technology Co is 438.94 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ever Supreme Bio Technology Co changed from 465.64 M TWD to 438.94 M TWD, representing a -5.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Ever Supreme Bio Technology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Ever Supreme Bio Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Ever Supreme Bio Technology Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Ever Supreme Bio Technology Co